Repros Announces Negative Opinion From the EMA for Enclomiphene

January 26, 2018 by Website Admin in

Repros Therapeutics today announced that the CHMP (Committee for Medicinal Products for Human Use) has formally issued a negative opinion for the centralized marketing authorization application for enclomiphene.

Tweet

Share

Pin it

Previous StoryLeading Leukemia Experts Join Moleculin’s Science Advisory Board Next StoryBellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the U.S.